Intranasal Sufentanil for Analgesia of Severe Sickle Cell Vaso-occlusive Pain Crisis in the Pediatric
Status:
Not yet recruiting
Trial end date:
2027-05-29
Target enrollment:
Participant gender:
Summary
Sickle cell disease (SCD) is characterized by an abnormal hemoglobin, the main protein in the
red blood cell. From the first months of life, acute obstruction of the vessels of the
microcirculation manifests as intense and unpredictable recurrent episodes of severe pain. In
the Emergency Department (ED), patients presenting with a vaso-occlusive crisis (VOC)
required a rapid evaluation and administration of pain relief therapies and hydration.
this strategy is based on an intranasal (IN) administration of Sufentanil at the initial
management of children with VOC, followed by morphine intravenous (IV) relay as soon as
possible, compared to the usual care procedure with IV morphine as soon as possible.
The hypothesis is that the use of this IN opioid at the beginning of the management of
children with VOC can reduce the time before being pain relieved. Indeed, the IN
administration make it easier and faster to administer.